Clinical Trial Update: An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

View source ↗

Summary

An observational study assessing ethnic differences in second-line pemetrexed treatment for non-small cell lung cancer, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Lung Neoplasms | Status: COMPLETED | Results posted: 2012-04-11